Venus Medtech (Hangzhou) Inc. (VMTHF)

Market Cap	55.28M -58.0%
Revenue (ttm)	37.56M -40.3%
Net Income	-68.34M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.1323
Previous Close	0.4219
Day's Range	0.1323 - 0.1323
52-Week Range	0.1323 - 0.4219
Beta	1.22
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 557
• Stock Exchange: OTCMKTS
• Ticker Symbol: VMTHF

Financial Performance

In 2025, Venus Medtech (Hangzhou)'s revenue was 306.79 million, a decrease of -34.84% compared to the previous year's 470.83 million. Losses were -407.69 million, -42.92% less than in 2024.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error